Abstract
Many solid tumours show an increased interstitial fluid pressure (IFP), which forms a barrier to transcapillary transport. This barrier is an obstacle in tumour treatment, as it results in inefficient uptake of therapeutic agents. There are a number of factors that contribute to increased IFP in the tumour, such as vessel abnormalities, fibrosis and contraction of the interstitial matrix. Lowering the tumour IFP with specific signal-transduction antagonists might be a useful approach to improving anticancer drug efficacy.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Alprostadil / pharmacology
-
Animals
-
Antineoplastic Agents / pharmacokinetics*
-
Biological Transport
-
Bradykinin / antagonists & inhibitors
-
Extracellular Fluid / physiology*
-
Humans
-
Hyaluronoglucosaminidase / pharmacology
-
Hydrostatic Pressure*
-
Mice
-
Neoplasms / blood supply
-
Neoplasms / drug therapy
-
Neoplasms / physiopathology*
-
Niacinamide / pharmacology
-
Platelet-Derived Growth Factor / antagonists & inhibitors
-
Signal Transduction / drug effects
-
Transforming Growth Factor beta / antagonists & inhibitors
-
Tumor Necrosis Factor-alpha / antagonists & inhibitors
-
Vascular Endothelial Growth Factor A / antagonists & inhibitors
Substances
-
Antineoplastic Agents
-
Platelet-Derived Growth Factor
-
Transforming Growth Factor beta
-
Tumor Necrosis Factor-alpha
-
Vascular Endothelial Growth Factor A
-
Niacinamide
-
Hyaluronoglucosaminidase
-
Alprostadil
-
Bradykinin